Thursday, March 07, 2019

DermWire TV: Annual Meeting Highlights; Ortho Derm's New Cash Pay Model

The annual meeting of the American Academy of Dermatology features updates in medical, surgical, and cosmetic dermatology. Practical Dermatology Chief medical editor Dr. Neal Bhatia highlighted the breadth of coverage at the meeting. DermTube caught up with multiple presenters who shared pearls from the AAD talks, including Diane Berson, MD, Shari Lipner, MD, Seemal Desai, MD, Rajani Katta, MD, and Joel L. Cohen, MD. Ortho Dermatologics launches a new cash pay prescription model. Company president Bill Humphries provides an overview.

Watch Video

Thursday, February 21, 2019

DermWireTV: Guidelines for PsO, SRT; Promising Data from Sienna

Two new guidelines from the American Academy of Dermatology and the National Psoriasis Foundation outline best practices for treating psoriasis, with a focus on comorbidities and biologic treatment. A new retrospective study shows a cure rate above 97 percent among older patients treated with superficial radiation therapy (SRT) for non-melanoma skin cancers in the lower extremities. Now new consensus guidelines suggest that the treatment should be first-line therapy for appropriate non-melanoma skin cancers in certain patients. Topline results from the pivotal trial of SNA-001 show statistically superior results for the topical agent in conjunction with an 810nm diode laser, compared to vehicle plus laser, for light hair.

Watch Video

Wednesday, February 06, 2019

DermWireTV: Approval for Evolus; Remembering Vic Narurkar, MD

The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by health insurers for certain drugs, tests, and treatments has led to serious or life-threatening events for patients, according results of a survey released by the American Medical Association. The dermatology and aesthetics community is mourning the death of Vic Narurkar, MD, a well-known researcher, author, and lecturer, and a past president of the American Society of Cosmetic Dermatology and Aesthetic Surgery.

Watch Video

Wednesday, January 23, 2019

DermWire TV: Antibiotics and Cosmetic Trends; Seysara Launches

Dermatologists are prescribing fewer antibiotics to manage acne and rosacea. But, the use of antibiotics after surgical procedures is on the rise. More than one third of American adults are considering a cosmetic treatment in 2019, results of a RealSelf survey show. Seysara (sarecycline), a novel tetracycline-derived oral antibiotic, is now commercially available from Almirall for the treatment of acne.

Watch Video

Tuesday, January 08, 2019

DermWireTV: Bristol-Myers Squibb Acquires Celgene, My UV Tracker, More

Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 Billion. Suneva® Medical partners with Healeon Medical, Inc. and Puregraft, LLC to add two new products to its aesthetics portfolio. Unveiled at the 2018 Consumer Electronics Show, the La Roche-Posay My Skin Track UV from L’Oreal is now available in Apple stores in the US and at apple.com. Pulse Biosciences' Nano-Pulse Stimulation technology achieved outstanding clearance rates on sebaceous hyperplasia lesions on the face, new data show.

Watch Video

Monday, December 17, 2018

DermWireTV: 2018 Therapeutics and Device Highlights

2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.

Watch Video

Thursday, December 06, 2018

DermWire TV: Updates from CSF, PsA Guidelines, Revance Data

Cosmetic Surgery Forum celebrates a decade of success. The meeting, featuring a panel of experts in both medical and cosmetic dermatology, wrapped up on Saturday and is already announcing plans for 2019. When it comes to psoriatic arthritis, prescribers should treat to target, new guidelines from the National Psoriasis Foundation and the American College of Rheumatology conclude. Revance Therapeutics may submit a Biologics License Application for long-acting neuromodulator daxibotulinumtoxinA for Injection, known as RT002, in the first half of next year.

Watch Video

Thursday, November 15, 2018

DermWireTV: Bryhali, Xepi Launches; Epionce's New Facility

Bryhali (halobetasol propionate) 0.01% Lotion from Ortho Dermatologics is now available for the topical treatment of plaque psoriasis in adults. Lawrence J. Green, MD a lead investigator on the Phase 3 studies speaks to DermWireTV. Botanical-based skincare company Epionce has a new 18,500 square foot manufacturing facility in Boise, ID. Younger individuals and females are more likely to use tanning beds and those who do are developing melanoma at an earlier age. Xepi (ozenoxacin) 1% Cream from Cutanea Life Sciences is now available for the treatment of impetigo in adults and in pediatric patients two months of age or older.

Watch Video

Wednesday, November 07, 2018

DermWire TV: Dupixent for Adolescents priority review, Restylane Lyft via cannulas, Hyperhidrosis Awareness

FDA grants priority review for Sanofi's and Regeneron's sBLA for Dupixent (dupilumab) for adolescents. Galderma’s Restylane Lyft is approved for use with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. The Skin Cancer Foundation’s 22nd annual Gala raises $600,000 to support the organization’s educational campaigns, community programs, and research initiatives.November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society has information at SweatHelp.org.

Watch Video

Thursday, October 25, 2018

DermWireTV: Updates from ASDS and ISHRS

The Annual meeting of the American Society for Dermatologic Surgery (ASDS) gathered experts in dermatologic surgery in Phoenix. Joel L. Cohen, MD and Shannon Humphrey, MD, who received the 2018 ASDS Award for Outstanding Service, discussed effective cosmetic consults. Diane Berson, MD addressed both medical and device-based approaches to managing acne. The 26th World Congress of the International Society of Hair Restoration Surgery (ISHRS) gathered leaders in hair restoration in Hollywood this month. Sharon Keene, MD spoke about the problem of hair loss in women. Nilofer Farjo, MB, ChB, BAO addressed evolving approaches to hair transplantation in patients with scalp psoriasis.

Watch Video

Tuesday, October 09, 2018

DermWireTV: FDA Approvals, Acne Insights, EPI Gets Cloderm

In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US may share a history of acne, but other data highlight the negative impact of acne on quality of life. EPI Health has acquired the rights to Cloderm Cream, 0.1% and its authorized generic from Promius Pharma, LLC.

Watch Video

Wednesday, September 26, 2018

DermWireTV: Galderma's Future, Allergan's Bonti Buy, and Sebacia Clearance

Nestle’s Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dollars, gaining the rights to EB-001A, the investigational botulinum neurotoxin type E formulation. EB-001A, currently in phase 2 trials, is characterized by a rapid onset of action of about 24 hours and a short duration of effect of about two to four weeks. Aclaris Therapeutics has been increasing its education to physicians, releasing a new video series featuring dermatologist Dr. Kavita Mariwala. Aclaris markets Eskata, the only product FDA approved for topical treatment of seborrheic keratosis or SK. Sebacia Microparticles are now FDA-cleared for use in the treatment of mild to moderate inflammatory acne.

Watch Video
Load More